利什曼病
Leishmaniasis.
作者信息
Piscopo Tonio V, Mallia Azzopardi Charles
机构信息
St Luke's Hospital, Guardamangia Hill, Guardamangia, MSD 09, Malta.
出版信息
Postgrad Med J. 2007 Feb;83(976):649-57. doi: 10.1136/pgmj.2006.047340corr1.
Abstract
Epidemiology, disease patterns, immunology, diagnosis, treatment and control measures of leishmaniasis are described. Various issues relating to leishmaniasis are highlighted: the relative lack of importance given to this disease compared with other infections, climate change and its possible impact on extension of endemicity of this infection, and new diagnostic tests which are improving diagnosis, especially in resource poor areas. Other important aspects discussed include the potential for newer oral therapy to change the way this disease is managed; Leishmania-HIV coinfection and groups at risk; and development of an effective vaccine.
摘要
本文描述了利什曼病的流行病学、疾病模式、免疫学、诊断、治疗及控制措施。文中强调了与利什曼病相关的各种问题：与其他感染相比，该疾病相对缺乏重视；气候变化及其对这种感染流行范围扩大的可能影响；以及正在改善诊断的新诊断测试，尤其是在资源匮乏地区。讨论的其他重要方面包括新型口服疗法改变该疾病管理方式的潜力；利什曼病与艾滋病毒合并感染及高危人群；以及有效疫苗的研发。
相似文献
1
Leishmaniasis.利什曼病
Postgrad Med J. 2007 Feb;83(976):649-57. doi: 10.1136/pgmj.2006.047340corr1.
2
[Leishmaniasis treatment].[利什曼病的治疗]
Arch Pediatr. 2010 Jun;17(6):838-9. doi: 10.1016/S0929-693X(10)70137-8.
3
[Leishmaniasis. Basic principles, clinical aspects, diagnosis and therapy].[利什曼病。基本原则、临床方面、诊断与治疗]
Dtsch Med Wochenschr. 1999 Jan 29;124(4):88-93. doi: 10.1055/s-2007-1024248.
4
Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).利什曼病的诊断与治疗：美国传染病学会（IDSA）和美国热带医学与卫生学会（ASTMH）发布的临床实践指南
Am J Trop Med Hyg. 2017 Jan 11;96(1):24-45. doi: 10.4269/ajtmh.16-84256. Epub 2016 Dec 7.
5
Leishmaniasis.利什曼病
Lancet. 1999 Oct 2;354(9185):1191-9. doi: 10.1016/S0140-6736(98)10178-2.
6
Leishmaniasis.利什曼病
Postgrad Med J. 2006 Oct;82(972):649-57. doi: 10.1136/pgmj.2006.047340.
7
Cutaneous leishmaniasis associated with visceral leishmaniasis in a case of acquired immunodeficiency syndrome (AIDS).一例获得性免疫缺陷综合征（艾滋病）患者中与内脏利什曼病相关的皮肤利什曼病。
Int J Dermatol. 2009 Jan;48(1):59-61. doi: 10.1111/j.1365-4632.2009.03870.x.
8
Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives.皮肤和黏膜利什曼病：临床视角。
J Am Acad Dermatol. 2015 Dec;73(6):897-908; quiz 909-10. doi: 10.1016/j.jaad.2014.08.051.
9
PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.合并感染HIV的利什曼病患者的皮肤利什曼病后皮肤黏膜病变及其他皮肤病变：与免疫反应相关的临床表现综述
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3258. doi: 10.1371/journal.pntd.0003258. eCollection 2014.
10
Cutaneous and mucocutaneous leishmaniasis.皮肤和黏膜利什曼病。
Dermatol Ther. 2009 Nov-Dec;22(6):491-502. doi: 10.1111/j.1529-8019.2009.01272.x.
引用本文的文献
1
Twenty-year evolution of Leishmania infantum infection in dogs in Valdeorras (Galicia, Northwestern Spain): implication of climatic factors and preventive measures.二十年来加利西亚瓦尔德奥拉斯（西班牙西北部）犬利什曼原虫感染的演变：气候因素的影响和预防措施。
Parasit Vectors. 2024 Jul 1;17(1):281. doi: 10.1186/s13071-024-06357-8.
2
Therapeutic Potential of Marine-Derived Cyclic Peptides as Antiparasitic Agents.海洋源环肽作为抗寄生虫药物的治疗潜力。
Mar Drugs. 2023 Nov 25;21(12):609. doi: 10.3390/md21120609.
3
Human Cutaneous Leishmaniasis in North Africa and Its Threats to Public Health: A Statistical Study Focused on Djelfa (Algeria).北非的人类皮肤利什曼病及其对公共卫生的威胁：一项以杰勒法（阿尔及利亚）为重点的统计研究
Microorganisms. 2023 Oct 22;11(10):2608. doi: 10.3390/microorganisms11102608.
4
Prevalence and Factors Related to Infection in Healthy Horses () from Eastern Spain.西班牙东部健康马匹感染的患病率及相关因素()
Animals (Basel). 2023 Sep 11;13(18):2889. doi: 10.3390/ani13182889.
5
Exploring Novel Drug Combinations: The Therapeutic Potential of Selanyl Derivatives for Leishmania Treatment.探索新型药物组合：硒烷衍生物治疗利什曼病的治疗潜力。
Molecules. 2023 Aug 3;28(15):5845. doi: 10.3390/molecules28155845.
6
Recent Advances in Chemotherapeutics for Leishmaniasis: Importance of the Cellular Biochemistry of the Parasite and Its Molecular Interaction with the Host.利什曼病化疗药物的最新进展：寄生虫细胞生物化学及其与宿主分子相互作用的重要性
Pathogens. 2023 May 12;12(5):706. doi: 10.3390/pathogens12050706.
7
High-risk spatiotemporal patterns of cutaneous leishmaniasis: a nationwide study in Iran from 2011 to 2020.高危时空模式的皮肤利什曼病：伊朗全国范围内 2011 至 2020 年的研究。
Infect Dis Poverty. 2023 May 15;12(1):49. doi: 10.1186/s40249-023-01103-1.
8
Next-Generation Leishmanization: Revisiting Molecular Targets for Selecting Genetically Engineered Live-Attenuated .下一代利什曼原虫接种疗法：重新审视用于选择基因工程减毒活疫苗的分子靶点
Microorganisms. 2023 Apr 16;11(4):1043. doi: 10.3390/microorganisms11041043.
9
Omics Approaches in Drug Development against Leishmaniasis: Current Scenario and Future Prospects.抗利什曼病药物研发中的组学方法：现状与未来展望
Pathogens. 2022 Dec 26;12(1):39. doi: 10.3390/pathogens12010039.
10
Visceral Leishmaniasis (Kala-Azar): A Triumph Against a Trickster Disease.内脏利什曼病（黑热病）：战胜一种狡猾疾病的胜利
Cureus. 2022 Jun 6;14(6):e25698. doi: 10.7759/cureus.25698. eCollection 2022 Jun.
本文引用的文献
1
Visceral leishmaniasis (kala-azar)--the Bihar (India) perspective.内脏利什曼病（黑热病）——比哈尔邦（印度）视角
J Infect. 2006 Jul;53(1):60-4. doi: 10.1016/j.jinf.2005.09.011. Epub 2005 Nov 2.
2
Advances in leishmaniasis.利什曼病的研究进展
Lancet. 2005;366(9496):1561-77. doi: 10.1016/S0140-6736(05)67629-5.
3
Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by a latex agglutination test.通过乳胶凝集试验检测内脏利什曼病患者尿液中的利什曼原虫抗原。
Am J Trop Med Hyg. 2005 Aug;73(2):269-71.
4
Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis.脂质体两性霉素B成功治疗巴西利什曼原虫皮肤利什曼病。
Br J Dermatol. 2005 Jul;153(1):203-5. doi: 10.1111/j.1365-2133.2005.06670.x.
5
Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region.利什曼病作为HIV感染患者的机会性感染：地中海地区228例病例协作研究中的复发和死亡决定因素
Eur J Clin Microbiol Infect Dis. 2005 Jun;24(6):411-8. doi: 10.1007/s10096-005-1342-6.
6
Positive Montenegro skin test among patients with sporotrichosis in Rio De Janeiro.里约热内卢孢子丝菌病患者中 Montenegro 皮肤试验呈阳性。
Acta Trop. 2005 Jan;93(1):41-7. doi: 10.1016/j.actatropica.2004.09.004.
7
Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.口服米替福新治疗免疫功能低下患者的利什曼病：39例HIV感染患者的同情用药
Clin Infect Dis. 2004 Nov 15;39(10):1520-3. doi: 10.1086/425359. Epub 2004 Oct 18.
8
Amphotericin B lipid complex: in visceral leishmaniasis.两性霉素B脂质复合物：用于内脏利什曼病。
Drugs. 2004;64(17):1905-11; discussion 1912-3. doi: 10.2165/00003495-200464170-00004.
9
Leishmaniasis: current situation and new perspectives.利什曼病：现状与新展望。
Comp Immunol Microbiol Infect Dis. 2004 Sep;27(5):305-18. doi: 10.1016/j.cimid.2004.03.004.
10
Miltefosine for new world cutaneous leishmaniasis.米替福新治疗新大陆皮肤利什曼病。
Clin Infect Dis. 2004 May 1;38(9):1266-72. doi: 10.1086/383321. Epub 2004 Apr 9.
Zotero 插件